Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel
Manos Perros, Chief Executive Officer of Entasis, commented, “Elizabeth brings invaluable experience and a strong track record to this role, as Entasis progresses into late-stage clinical development and potentially commercialization. Elizabeth’s depth of experience and her proven expertise in corporate governance, compliance, intellectual property strategy and licensing, make her uniquely qualified to help our team as we continue to develop our company.”
“This is an exciting time to be joining Entasis as the Company prepares to transition into a commercial-stage company with multiple late-stage clinical candidates,” said Ms. Keiley. “I aim to utilize my experience in navigating the legal and regulatory requirements for development and commercialization of Entasis’ innovative pathogen-specific, multi-drug resistant antimicrobial therapies.”
Ms. Keiley is a seasoned attorney and has served in several in-house counsel positions for various healthcare companies. Prior to joining Entasis, Ms. Keiley was Senior Vice President, General Counsel at Oxford Immunotec, a
Ms. Keiley earned her bachelor’s degree in psychology and philosophy from
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Investor Relations Contact
Source: Entasis Therapeutics Holdings Inc.